Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

Living with the rare condition of IgA nephropathy can feel lonely. Patient advocate Stuart Miller shares his treatment journey and how to stay connected with those who understand. Share on ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

"Today's approval marks an important milestone for people living with IgA nephropathy, offering a new option that can be seamlessly integrated into their existing treatment plan, with no REMS ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat patients with the rare kidney disease immunoglobulin A nephropathy ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.